期刊文献+

调强放疗对比三维适形放疗治疗非小细胞肺癌的疗效及对血清CEA、CYFRA21-1的影响 被引量:21

Therapeutic Effect of Intensity-modulated Radiotherapy and Three-dimensional Conformal Radiotherapy for Non-small Cell Lung Cancer and its Effect on Serum CEA and CYFRA21-1
下载PDF
导出
摘要 目的探讨对非小细胞肺癌进行调强放疗(IMRT)与三维适形放疗(3D-CRT)的临床效果,并观察血清CEA、CYFRA21-1的变化。方法将77例非小细胞肺癌患者按随机数字法分为2组,38例行IMRT,设为甲组;39组行3D-CRT设为乙组。观察2组临床疗效及并发症情况;并对比治疗前后2组血清癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)水平变化。结果2组患者临床有效率无明显差异(P>0.05),但甲组放疗后并发症发生率相比乙组明显更低(P<0.05),且血清CEA、CYFRA21-1水平明显低于乙组(P<0.05)。结论IMRT、3D-CRT在非小细胞肺癌治疗中均有良好疗效,且IMRT可有效降低非小细胞肺癌患者放疗后并发症发生率、降低血清CEA及CYFRA21-1水平,值得推广。 Objective To analyze the clinical effects of IMRT and 3D-CRT in non-small cell lung cancer,and to observe the effects of serum CEA and CYFRA21-1.Methods 77 patients with non-small cell lung cancer were enrolled in the study.According to the random number method,they were divided into 2 groups.38 patients underwent IMRT and were assigned to group A and 39 groups.3D-CRT was set as group B.The clinical efficacy and complications of the 2 groups were observed.The levels of serum carcinoembryonic antigen(CEA)and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)were compared before and after treatment.Results There was no significant difference in clinical efficacy between the 2 groups(P>0.05).However,the incidence of complications after radiotherapy was significantly lower in group A than in group B(P<0.05),and serum CEA and CYFRA21-1 levels were significantly lower in group B(P<0.05).Conclusion IMRT and 3D-CRT have good curative effect in the treatment of non-small cell lung cancer,and IMRT can effectively reduce the incidence of postoperative complications of non-small cell lung cancer and reduce the levels of serum CEA and CYFRA21-1,which is worthy of promotion.
作者 孙祝 雍翔 孙宇 张武 赵玉魁 SUN Zhu;YONG Xiang;SUN Yu(General Hospital of North Anhui Coal and Electricity Group,Suzhou,234000)
出处 《实用癌症杂志》 2020年第5期774-777,共4页 The Practical Journal of Cancer
关键词 三维适形放疗 非小细胞肺癌 调强放疗 细胞角蛋白19片段抗原21-1 癌胚抗原 Three-dimensional conformal radiotherapy Non-small cell lung cancer Intensity-modulated radiotherapy Cytokeratin 19 fragment antigen 21-1 Carcinoembry
  • 相关文献

参考文献15

二级参考文献185

  • 1王颖轶,陈书长.肿瘤标志物对晚期非小细胞肺癌患者放疗疗效的评估价值[J].实用癌症杂志,2014,29(1):23-25. 被引量:12
  • 2陈允硕,吴健民.肿瘤标志物临床检测的基本原则(建议稿)[J].中华检验医学杂志,2004,27(6):393-393. 被引量:35
  • 3曾显声,周燕斌.肺癌血清肿瘤标志物的研究现状[J].国际内科学杂志,2007,34(2):73-76. 被引量:51
  • 4赫捷,陈万青主编.2012中国肿瘤登记年报.第1版.北京:军事医学科学出版社,2012.72.
  • 5Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 2008, 83:584-594.
  • 6Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res, 2006,12:7232-7241.
  • 7Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol, 2008, 26:2442-2449.
  • 8Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68:198-203.
  • 9Su KY, Chen HY, u KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non?small-cell lung cancer. J Clin Oncol, 2012, 30 :433440.
  • 10Soda M, Choi YL, Enomoto M, et al. Identification of the transfonning EMIA-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448 :561-566.

共引文献287

同被引文献210

引证文献21

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部